- NervGen Pharma (NGEN) reports its first subject dosed in Phase 1 Clinical Trial of NVG-291
- The study, conducted in healthy subjects, is a two-part, triple-blind, randomized, placebo-controlled, first-in-human stud
- The primary objective of the trial is to evaluate the safety, tolerability, and pharmacokinetics of NVG-291
- NervGen also plans to initiate Phase 2 trials in spinal cord injury and multiple sclerosis with each of these trials planned to start in 2022
- NervGen is restoring life’s potential by developing innovative treatments for nerve damage and neurodegenerative diseases
- NervGen Pharma Corp. (NGEN) is down 1.32 per cent and is trading at C$1.50 at 11:56 am ET
NervGen Pharma Corp. (NGEN) reported that the first subject has been dosed with NVG-291 in the company’s phase 1 clinical trial in healthy volunteers.
“Dosing the first subject in the phase 1 clinical trial represents an important and exciting milestone for NervGen, its founders, and particularly for patients with nerve damage that currently are in great need of new and novel therapies,” stated Paul Brennan, NervGen’s President and CEO.
“NVG-291 has the potential to redefine how nerve damage is treated across multiple indications, whether caused by trauma or chronic disease,” added Brennan.
The phase 1 NVG-291 clinical trial is being conducted in Australia by Novotech (Australia) Pty Limited, a leading full-service contract research organization.
The study, conducted in healthy subjects, is a two-part, triple-blind, randomized, placebo-controlled, first-in-human study.
Part one of the study is the single ascending dose portion of the trial and will be conducted in females.
Part two of the study is the multiple ascending dose portion of the trial and will be conducted in post-menopausal females. The primary objective of the trial is to evaluate the safety, tolerability, and pharmacokinetics of NVG-291.
Upon completion of the multiple ascending dose portion of the trial in healthy subjects, NervGen intends to initiate a multi-dose Alzheimer’s disease patient cohort as a Phase 1b program.
Concurrently, NervGen also plans to initiate Phase 2 trials in spinal cord injury and multiple sclerosis with each of these trials planned to start in 2022.
NVG-291 is an inhibitor of PTPσ, a promising target for reducing the clinical effects of nerve damage, either as a result of trauma, such as in the case of spinal cord injury, traumatic brain injury or stroke, or neurodegenerative diseases, such as multiple sclerosis or Alzheimer’s disease.
NervGen is restoring life’s potential by developing innovative treatments for nerve damage and neurodegenerative diseases.
NervGen Pharma Corp. (NGEN) is down 1.32 per cent and is trading at C$1.50 at 11:56 am ET.
